Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-09-16
2008-09-16
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S158100, C530S387100, C530S388100, C530S388200, C530S388230
Reexamination Certificate
active
11582153
ABSTRACT:
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5075236 (1991-12-01), Yone et al.
patent: 5223395 (1993-06-01), Gero
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5360716 (1994-11-01), Ohmoto et al.
patent: 5436154 (1995-07-01), Barbanti et al.
patent: 5506265 (1996-04-01), Blitstein-Willinger
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5700788 (1997-12-01), Mongelli et al.
patent: 5730975 (1998-03-01), Hotamisligil et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5776947 (1998-07-01), Kroemer et al.
patent: 5874441 (1999-02-01), Magolda et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5959087 (1999-09-01), Rathjen et al.
patent: 5993833 (1999-11-01), DeLacharriere et al.
patent: 5994510 (1999-11-01), Adair et al.
patent: 6015558 (2000-01-01), Hotamisligil et al.
patent: 6172202 (2001-01-01), Marcucci et al.
patent: 6190691 (2001-02-01), Mak
patent: 6194451 (2001-02-01), Alpegiani et al.
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6309640 (2001-10-01), Cerami et al.
patent: 6419927 (2002-07-01), Cerami et al.
patent: 6790444 (2004-09-01), Le et al.
patent: 6835823 (2004-12-01), Le et al.
patent: 6914128 (2005-07-01), Salfeld et al.
patent: 6991791 (2006-01-01), Le et al.
patent: 7070775 (2006-07-01), Le et al.
patent: 7101674 (2006-09-01), Le et al.
patent: 7128907 (2006-10-01), Le et al.
patent: 7128908 (2006-10-01), Le et al.
patent: 7135178 (2006-11-01), Le et al.
patent: 7135179 (2006-11-01), Le et al.
patent: 7138118 (2006-11-01), Le et al.
patent: 7160542 (2007-01-01), Le et al.
patent: 7160543 (2007-01-01), Le et al.
patent: 7160995 (2007-01-01), Le et al.
patent: 7166284 (2007-01-01), Le et al.
patent: 7169386 (2007-01-01), Le et al.
patent: 7169388 (2007-01-01), Le et al.
patent: 7179466 (2007-02-01), Le et al.
patent: 7179893 (2007-02-01), Le et al.
patent: 7192584 (2007-03-01), Le et al.
patent: 7204985 (2007-04-01), Le et al.
patent: 7214376 (2007-05-01), Le et al.
patent: 7223396 (2007-05-01), Le et al.
patent: 7226593 (2007-06-01), Le et al.
patent: 7227003 (2007-06-01), Le et al.
patent: 7252823 (2007-08-01), Le et al.
patent: 7276239 (2007-10-01), Le et al.
patent: 2002/0022720 (2002-02-01), Le et al.
patent: 2002/0114805 (2002-08-01), Le et al.
patent: 2002/0146419 (2002-10-01), Le et al.
patent: 2003/0054004 (2003-03-01), Le et al.
patent: 2003/0147891 (2003-08-01), Le et al.
patent: 2003/0181695 (2003-09-01), Le et al.
patent: 2003/0194402 (2003-10-01), Le et al.
patent: 2004/0115200 (2004-06-01), Le et al.
patent: 2004/0138427 (2004-07-01), Le et al.
patent: 2005/0249735 (2005-11-01), Le et al.
patent: 2005/0255104 (2005-11-01), Le et al.
patent: 2005/0260201 (2005-11-01), Le et al.
patent: 2006/0024310 (2006-02-01), Le et al.
patent: 2006/0140946 (2006-06-01), Le et al.
patent: 2006/0140949 (2006-06-01), Le et al.
patent: 2007/0087003 (2007-04-01), Le et al.
patent: 2007/0141057 (2007-06-01), Le et al.
patent: 2007/0196373 (2007-08-01), Le et al.
patent: 0212489 (1987-03-01), None
patent: 0218868 (1987-04-01), None
patent: 0260610 (1988-03-01), None
patent: 0350690 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0387095 (1990-03-01), None
patent: 0380068 (1990-08-01), None
patent: 0393438 (1990-10-01), None
patent: 0453898 (1991-10-01), None
patent: 0486526 (1992-05-01), None
patent: 0512528 (1992-11-01), None
patent: 0526905 (1993-02-01), None
patent: 0288 088 (1994-03-01), None
patent: 0585705 (1994-03-01), None
patent: 0614984 (1994-09-01), None
patent: 0412486 (1994-11-01), None
patent: 0101681 (1994-12-01), None
patent: 0398327 (1995-03-01), None
patent: 0433900 (1995-09-01), None
patent: 0706795 (1996-04-01), None
patent: 0663836 (1997-07-01), None
patent: 0869179 (1998-10-01), None
patent: 0861850 (2002-05-01), None
patent: 0867509 (2002-08-01), None
patent: 0870827 (2004-03-01), None
patent: 61-047500 (1986-03-01), None
patent: 02-227095 (1990-09-01), None
patent: WO 89/08460 (1989-09-01), None
patent: WO 90/00902 (1990-02-01), None
patent: WO 90/01950 (1990-03-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 91/04054 (1991-04-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 92/01472 (1992-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/13095 (1992-08-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 94/08609 (1994-04-01), None
patent: WO 94/08619 (1994-04-01), None
patent: 0308378 (1994-11-01), None
patent: WO 98/51344 (1998-11-01), None
patent: WO 00/062790 (2000-10-01), None
patent: WO 2004/050683 (2004-06-01), None
patent: WO 2006/065975 (2006-06-01), None
Toussirot, E. and Wendling, D., “Recent Progress in Anklosing Spondylitis Treatment,”Expert. Opin. Pharmacother., 4(1): 1-12 (2003).
Braun, J. et al., “Treatment of Active Anklosing Spondylitis with Infliximab: A Randomised Controlled Multicentre Trial,”Lancet, 359(9313): 1187-1193 (2002).
St. Clair, E. W., et al., “Infliximab Treatment for Rheumatic Disease: Clinical and Radiological Efficacy,”Ann. Rheum. Dis., 61(Suppl 2): ii67-ii69 (2002).
Bard, F., et al. “Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease,”Nat. Medicine, 6(8): 916-919 (2000).
Brok, H.P.M. et al., “Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using and Anti-IL-12p40 Monoclonal Antibody,”J. Immunol., 6554-6563 (2002).
Cornillie, F. et al., “Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease,”Aliment. Pharmacol. Ther., 15: 463-473 (2000).
Geysen, H.M. et al., “A Synthetic Strategy for Epitope Mapping,”In Proc. Tenth Amer. Peptide Symposium, pp. 519-523 (Garland R. Marshall, ed. 1987).
Berkow, R. (ed), InMerck Manual of Diagnosis and Therapy, (NJ: Merck & Co, Inc.) 16th Ed., pp. 1407-1409 (1992).
Beck, J. et al., “Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations?,”Acta. Neurol. Scand., 78: 318-323 (1988).
Beck, J. et al., “Increased Production of TNF-α in Multiple Sclerosis,”Immunobiology, 175(1-2): 91-92 (1987) Abstract.
Selmaj, K. et al., “Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervouse Tissue,”Neuroimmunology, 16(1): 159 (1987) Abstract.
Pardridge, W.M., “New Approaches to Drug Delivery Through the Blood-Brain Barrier,”Trends in Biotechnology, 12(6): 239-245 (1994) pp. 239-245 Abstract.
Selmaj, K., et al., “Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination,”Ann. Neurol., 30: 694-700 (1991).
Chofflon, M., et al., “Tumor Necrosis Factor Alpha Production as a Possible Predictor of Relapse in Patients with Multiple Sclerosis,”Eur. Cy
Daddona Peter
Ghrayeb John
Knight David
Le Junming
Siegel Scott
Centocor, Inc.
Gambel Phillip
Hamilton Brook Smith & Reynolds P.C.
New York University
LandOfFree
Methods of inhibiting TNFα activity in the blood of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting TNFα activity in the blood of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting TNFα activity in the blood of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3952215